Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Axsome Thera (AXSM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 499,533
  • Shares Outstanding, K 33,280
  • Annual Sales, $ 0 K
  • Annual Income, $ -30,970 K
  • 60-Month Beta 3.48
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 473.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.31
  • Number of Estimates 2
  • High Estimate -0.27
  • Low Estimate -0.35
  • Prior Year -0.19
  • Growth Rate Est. (year over year) -63.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.48 +30.75%
on 03/19/19
16.80 -10.65%
on 03/27/19
+3.54 (+30.86%)
since 03/18/19
3-Month
7.63 +96.72%
on 01/29/19
16.80 -10.65%
on 03/27/19
+6.85 (+83.95%)
since 01/18/19
52-Week
1.94 +673.71%
on 12/27/18
16.80 -10.65%
on 03/27/19
+12.41 (+477.31%)
since 04/18/18

Most Recent Stories

More News
Biotech Brief: Optimism Rising for Cancer Treatment Advancements in 2019

Financialnewsmedia.com News Commentary

RNN : 6.24 (-0.95%)
TEVA : 14.36 (+0.98%)
AXSM : 15.01 (+0.74%)
Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal

Key highlights of the past week are collaborations and pipeline updates.

CELG : 93.76 (-0.57%)
NVO : 48.39 (-0.25%)
VRTX : 168.16 (+0.71%)
GILD : 62.95 (-0.47%)
FCSC : 2.24 (-0.88%)
BMY : 45.52 (-0.61%)
AXSM : 15.01 (+0.74%)
Axsome's AXS-05 Meets Goal in Phase II Study, Shares Up

Axsome's (AXSM) mid-stage candidate, AXS-05, achieves the primary endpoint in a phase II study as a smoking cessation treatment. Shares rise.

PDLI : 3.58 (+3.47%)
JNJ : 137.52 (-0.72%)
GSK : 39.85 (-0.33%)
AXSM : 15.01 (+0.74%)
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Smoking Cessation

Demonstrated statistically significant reduction in daily smoking compared to active comparator (p=0.0016)

AXSM : 15.01 (+0.74%)
Market Trends Toward New Normal in BlackBerry, Axsome Therapeutics, Pulse Biosciences, Whitestone REIT, Anworth Mortgage Asset, and Synchronoss Technologies -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of BlackBerry Limited (NYSE:BB), Axsome...

BB : 9.21 (unch)
WSR : 12.25 (+0.91%)
PLSE : 15.58 (+0.13%)
ANH : 4.10 (unch)
SNCR : 5.44 (-3.55%)
AXSM : 15.01 (+0.74%)
Implied Volatility Surging for Axsome Therapeutics (AXSM) Stock Options

Investors need to pay close attention to Axsome Therapeutics (AXSM) stock based on the movements in the options market lately.

AXSM : 15.01 (+0.74%)
Axsome's Depression Drug Gets Breakthrough Therapy Status

Axsome (AXSM) announces that the FDA has granted Breakthrough Therapy designation to AXS-05 for the treatment of major depressive disorder (MDD).

JNJ : 137.52 (-0.72%)
AGN : 140.31 (+0.20%)
GSK : 39.85 (-0.33%)
AXSM : 15.01 (+0.74%)
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Major Depressive Disorder

Designation offers potential for expedited development and review

AXSM : 15.01 (+0.74%)
Axsome: 4Q Earnings Snapshot

NEW YORK (AP) _ Axsome Therapeutics Inc. (AXSM) on Thursday reported a loss of $9.6 million in its fourth quarter.

AXSM : 15.01 (+0.74%)
Axsome Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

Company to host conference call today at 8:00 AM Eastern

AXSM : 15.01 (+0.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade AXSM with:

Business Summary

Axsome Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing novel therapies for the management of pain and other central nervous system disorders. Its product candidate portfolio consists of AXS-02 and AXS-05 which are in clinical trial stage. Axsome Therapeutics, Inc....

See More

Key Turning Points

2nd Resistance Point 15.95
1st Resistance Point 15.48
Last Price 15.01
1st Support Level 14.44
2nd Support Level 13.86

See More

52-Week High 16.80
Last Price 15.01
Fibonacci 61.8% 11.12
Fibonacci 50% 9.37
Fibonacci 38.2% 7.62
52-Week Low 1.94

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar